F8 and hemophilia: The gene therapy option for hemophilia remains a viable alternative because of the amount of cell types that are capable of synthesizing biologically active FVIII (synthesized basically in endothelial cells, including liver sinusoidal) and FIX (fundamentally synthesized in the hepatocytes) following gene transfer.